Jazz Pharmaceuticals (Dublin, Ireland) and The University of Texas MD Anderson Cancer Center (Houston, USA) announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
The joint effort brings together MD Anderson’s translational medicine and clinical research capabilities with Jazz’s hematology/oncology portfolio, including its FDA-approved medicines as well as current and potential future investigational therapies.
Jazz and MD Anderson will pursue research opportunities in areas of high unmet need. The initial focus of the collaboration is to evaluate and generate additional data for Vyxeos® (daunorubicin and cytarabine) liposome for injection, in new patient populations and in combination with other therapies. Vyxeos received FDA approval in August 2017 for the treatment of adults with newly-diagnosed therapy-related (t-AML) or AML with myelodysplasia-related changes (AML-MRC), which represents part of high-risk or secondary AML populations.
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention.
Jazz Pharmaceuticals, an international biopharmaceutical company, has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.